Table 1

Patient demographics and treatment outcomes

PatientGenderCurrent age (years)Age at onset (years)Antibody statusMyasthenia Gravis Foundation America pre-rituximabPrevious treatmentsPostrituximab post-intervention status
1F115AChR Ab+IVaTx (normal thymus) PRED, PEX, IVIgCSR
2F2014AChR Ab+VTx (hyperplasia), PRED AZA, MMF, PEX, CYCCSR
3F2413AChR Ab+IIIbTx (hyperplasia), PRED AZA, IVIg, PEXU
4F2511 (LEMS)VGCC Ab+IVaPRED, AZA, CIC, MMF IVIg, PEXI
5F292MuSK Ab+IVbPRED, AZA, CIC, IVIg PEXPR
6F3429AChR Ab+IIIbTx (hyperplasia), PRED AZA, MTX, MMF, IVIgU
7F358AChR Ab+IVbTx (hyperplasia), PRED AZA, MTX, CIC, IVIg, PEXW
8F3628AChR Ab+VTx (hyperplasia), PRED AZA, IVIgI
9F4036MuSK Ab+VPRED, MMF, IVIg, PEXI
10M4641 (LEMS)VGCC Ab+IVbPRED, AZA, MTX, CIC IVIg, PEXMM-1
11F4642AChR Ab+VTx (thymoma), PRED AZA, IVIgU
12F5249MuSK Ab+IVbPRED, AZA, MMF, IVIg PEXI
  • AChR Ab, acetylcholine receptor antibody; AZA, azathioprine; CIC, ciclosporin; CSR, complete stable remission; CYC, cyclophosphamide; I, improved; MM-1, minimal manifestations; MMF, mycophenolate; MTX, methotrexate; MuSK Ab, muscle-specific tyrosine kinase antibody; PR, pharmacological remission; PRED, prednisolone; Tx, thymectomy; U, unchanged; VGCC Ab, voltage-gated calcium channel antibody; W, worse.